148 related articles for article (PubMed ID: 36219456)
1. Immunodominance hierarchy after seasonal influenza vaccination.
Sánchez-de Prada L; Sanz-Muñoz I; de Lejarazu RO; Eiros JM; García-Sastre A; Aydillo T
Emerg Microbes Infect; 2022 Dec; 11(1):2670-2679. PubMed ID: 36219456
[TBL] [Abstract][Full Text] [Related]
2. The immunodominance of antigenic site Sb on the H1 influenza virus hemagglutinin increases with high immunoglobulin titers of the cohorts and with young age, but not sex.
Martínez JL; Lemus N; Lai TY; Mishra M; González-Domínguez I; Puente-Massaguer E; Loganathan M; Francis B; Samanovic MI; Krammer F; Mulligan MJ; Simon V; Palese P; Sun W
Vaccine; 2024 May; 42(14):3365-3373. PubMed ID: 38627145
[TBL] [Abstract][Full Text] [Related]
3. Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice.
Broecker F; Liu STH; Sun W; Krammer F; Simon V; Palese P
J Virol; 2018 Oct; 92(20):. PubMed ID: 30045991
[TBL] [Abstract][Full Text] [Related]
4. Fc functional antibody responses to adjuvanted versus unadjuvanted seasonal influenza vaccination in community-dwelling older adults.
Vanderven HA; Barr I; Reynaldi A; Wheatley AK; Wines BD; Davenport MP; Hogarth PM; Kent SJ
Vaccine; 2020 Feb; 38(10):2368-2377. PubMed ID: 32035709
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
Forster AH; Witham K; Depelsenaire ACI; Veitch M; Wells JW; Wheatley A; Pryor M; Lickliter JD; Francis B; Rockman S; Bodle J; Treasure P; Hickling J; Fernando GJP
PLoS Med; 2020 Mar; 17(3):e1003024. PubMed ID: 32181756
[TBL] [Abstract][Full Text] [Related]
6. Influenza A haemagglutinin specific IgG responses in children and adults after seasonal trivalent live attenuated influenza vaccination.
Islam S; Mohn KG; Krammer F; Sanne M; Bredholt G; Jul-Larsen Å; Tete SM; Zhou F; Brokstad KA; Cox RJ
Vaccine; 2017 Oct; 35(42):5666-5673. PubMed ID: 28899626
[TBL] [Abstract][Full Text] [Related]
7. Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance.
Liu STH; Behzadi MA; Sun W; Freyn AW; Liu WC; Broecker F; Albrecht RA; Bouvier NM; Simon V; Nachbagauer R; Krammer F; Palese P
J Clin Invest; 2018 Nov; 128(11):4992-4996. PubMed ID: 30188868
[TBL] [Abstract][Full Text] [Related]
8. Minor changes in the hemagglutinin of influenza A(H1N1)2009 virus alter its antigenic properties.
Strengell M; Ikonen N; Ziegler T; Julkunen I
PLoS One; 2011; 6(10):e25848. PubMed ID: 22022458
[TBL] [Abstract][Full Text] [Related]
9. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
[TBL] [Abstract][Full Text] [Related]
10. Directed selection of influenza virus produces antigenic variants that match circulating human virus isolates and escape from vaccine-mediated immune protection.
DeDiego ML; Anderson CS; Yang H; Holden-Wiltse J; Fitzgerald T; Treanor JJ; Topham DJ
Immunology; 2016 Jun; 148(2):160-73. PubMed ID: 26854888
[TBL] [Abstract][Full Text] [Related]
11. Epitope mapping of the 2009 pandemic and the A/Brisbane/59/2007 seasonal (H1N1) influenza virus haemagglutinins using mAbs and escape mutants.
Retamal M; Abed Y; Corbeil J; Boivin G
J Gen Virol; 2014 Nov; 95(Pt 11):2377-2389. PubMed ID: 25078301
[TBL] [Abstract][Full Text] [Related]
12. A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery system.
Gorse GJ; Grimes S; Buck H; Mulla H; White P; Hill H; May J; Frey SE; Blackburn P
Vaccine; 2022 Feb; 40(9):1271-1281. PubMed ID: 35125219
[TBL] [Abstract][Full Text] [Related]
13. Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.
Allen JD; Jang H; DiNapoli J; Kleanthous H; Ross TM
J Virol; 2019 Feb; 93(3):. PubMed ID: 30429350
[TBL] [Abstract][Full Text] [Related]
14. Broadly Reactive IgG Responses to Heterologous H5 Prime-Boost Influenza Vaccination Are Shaped by Antigenic Relatedness to Priming Strains.
Wang J; Li D; Perry S; Hilchey SP; Wiltse A; Treanor JJ; Sangster MY; Zand MS
mBio; 2021 Aug; 12(4):e0044921. PubMed ID: 34225490
[TBL] [Abstract][Full Text] [Related]
15. A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly.
Mullikin M; Tan L; Jansen JP; Van Ranst M; Farkas N; Petri E
Infect Dis Ther; 2015 Dec; 4(4):459-87. PubMed ID: 26350238
[TBL] [Abstract][Full Text] [Related]
16. Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants.
Wong TM; Allen JD; Bebin-Blackwell AG; Carter DM; Alefantis T; DiNapoli J; Kleanthous H; Ross TM
J Virol; 2017 Dec; 91(24):. PubMed ID: 28978710
[TBL] [Abstract][Full Text] [Related]
17. Immunodominance and Antigenic Variation of Influenza Virus Hemagglutinin: Implications for Design of Universal Vaccine Immunogens.
Zost SJ; Wu NC; Hensley SE; Wilson IA
J Infect Dis; 2019 Apr; 219(Suppl_1):S38-S45. PubMed ID: 30535315
[TBL] [Abstract][Full Text] [Related]
18. MAS-1, a novel water-in-oil adjuvant/delivery system, with reduced seasonal influenza vaccine hemagglutinin dose may enhance potency, durability and cross-reactivity of antibody responses in the elderly.
Gorse GJ; Grimes S; Buck H; Mulla H; White P; Hill H; May J; Frey SE; Blackburn P
Vaccine; 2022 Mar; 40(10):1472-1482. PubMed ID: 35125224
[TBL] [Abstract][Full Text] [Related]
19. Comparison of A(H3N2) Neutralizing Antibody Responses Elicited by 2018-2019 Season Quadrivalent Influenza Vaccines Derived from Eggs, Cells, and Recombinant Hemagglutinin.
Wang W; Alvarado-Facundo E; Vassell R; Collins L; Colombo RE; Ganesan A; Geaney C; Hrncir D; Lalani T; Markelz AE; Maves RC; McClenathan B; Mende K; Richard SA; Schofield C; Seshadri S; Spooner C; Utz GC; Warkentien TE; Levine M; Coles CL; Burgess TH; Eichelberger M; Weiss CD
Clin Infect Dis; 2021 Dec; 73(11):e4312-e4320. PubMed ID: 32898271
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults.
Essink B; Fierro C; Rosen J; Figueroa AL; Zhang B; Verhoeven C; Edelman J; Smolenov I
Vaccine; 2020 Jan; 38(2):242-250. PubMed ID: 31635976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
